Xtalks – Biotech Blogs - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Xtalks – Biotech Blogs

Xtalks – Biotech Blogs

Publication
0 followers

Independent platform with expert-written pieces on biotech R&D and industry trends.

Recent Posts

How Takeda Is Harnessing RWE, Patient Insights and Human-Focused AI to Advance Global Access
News•Feb 26, 2026

How Takeda Is Harnessing RWE, Patient Insights and Human-Focused AI to Advance Global Access

Takeda is leveraging real‑world evidence (RWE) and human‑focused AI to reshape clinical trial design, patient access, and global market strategies. Chief Medical Officer Awny Farajallah highlights three pillars: robust evidence generation, capability building, and early patient access. RWE is used to broaden eligibility criteria, create synthetic control arms for rare diseases, and uncover unmet needs in underserved groups such as African‑American multiple myeloma patients. AI tools are deployed to accelerate drug discovery, improve manufacturing quality, and deliver actionable insights for clinicians, payers, and policymakers, while partnerships drive vaccine distribution and infrastructure development.

By Xtalks – Biotech Blogs
Leading Women CEOs Across Pharma and Biotech: A 2026 Snapshot
News•Feb 25, 2026

Leading Women CEOs Across Pharma and Biotech: A 2026 Snapshot

2026’s leading women CEOs in pharma and biotech are steering some of the industry’s biggest strategic moves, from multi‑billion‑dollar investments to landmark FDA approvals. The list includes Julie Kim’s upcoming Takeda leadership, Emma Walmsley’s transition at GSK, Reshma Kewalramani’s growth...

By Xtalks – Biotech Blogs
Rare Disease Day Insight: Epilepsy Care Gaps in Pregnancy with UCB’s Andrea Wilkinson — Episode 244
News•Feb 25, 2026

Rare Disease Day Insight: Epilepsy Care Gaps in Pregnancy with UCB’s Andrea Wilkinson — Episode 244

The Xtalks Life Science Podcast’s Episode 244 spotlights a persistent gap in epilepsy care for pregnant women, noting that fewer than 5% of clinical trials include this population. Andrea Wilkinson, UCB’s Global Head of Patient Engagement & Advocacy, discusses new...

By Xtalks – Biotech Blogs
Filkri Becomes Fifth FDA-Approved Neupogen Biosimilar
News•Feb 24, 2026

Filkri Becomes Fifth FDA-Approved Neupogen Biosimilar

Accord BioPharma’s Filkri (filgrastim‑laha) received FDA approval as the fifth biosimilar to Amgen’s Neupogen. The indication set mirrors Neupogen’s, covering chemotherapy‑induced neutropenia, AML, bone‑marrow transplant, severe chronic neutropenia, and radiation‑induced syndrome. Approval was based on two randomized trials in healthy...

By Xtalks – Biotech Blogs
Denifanstat Posts Positive Phase III Results for Acne Treatment
News•Feb 23, 2026

Denifanstat Posts Positive Phase III Results for Acne Treatment

Ascletis Pharma announced that its oral fatty‑acid‑synthase inhibitor denifanstat (ASC40) achieved positive Phase III results in moderate‑to‑severe acne vulgaris. In a 480‑patient double‑blind trial, 33% of participants reached clear or almost‑clear skin versus 15% on placebo, and an open‑label safety study...

By Xtalks – Biotech Blogs
Eli Lilly Invests $3.5B in Pennsylvania to Scale Next‑Gen Obesity Drug Manufacturing
News•Feb 20, 2026

Eli Lilly Invests $3.5B in Pennsylvania to Scale Next‑Gen Obesity Drug Manufacturing

Eli Lilly announced a $3.5 billion investment to build a new injectable‑medicine plant in Lehigh Valley, Pennsylvania. The facility, slated to break ground in 2026 and run by 2031, will focus on next‑generation obesity and metabolic drugs such as the triple‑agonist retatrutide....

By Xtalks – Biotech Blogs
Novartis Breaks Ground on $23B Biomedical Research Hub in San Diego
News•Feb 20, 2026

Novartis Breaks Ground on $23B Biomedical Research Hub in San Diego

Novartis began construction of a new biomedical research hub in San Diego. The 466,000‑sq‑ft center, part of a $23 billion US R&D and manufacturing program, will house about 1,000 researchers and target neuroscience, oncology, global health, and age‑related diseases. Scheduled to...

By Xtalks – Biotech Blogs
Topical Adquey (Difamilast) Wins FDA Approval for Atopic Dermatitis
News•Feb 20, 2026

Topical Adquey (Difamilast) Wins FDA Approval for Atopic Dermatitis

The U.S. Food and Drug Administration has granted approval to Adquey, a 1% difamilast topical ointment, for the treatment of mild-to-moderate atopic dermatitis in patients two years and older. Developed by Otsuka and licensed to Acrotech Biopharma, the product is...

By Xtalks – Biotech Blogs
Genentech’s Fenebrutinib Yields Positive Results in Phase III MS Trial
News•Feb 18, 2026

Genentech’s Fenebrutinib Yields Positive Results in Phase III MS Trial

Genentech’s oral BTK inhibitor fenebrutinib met its primary endpoint in the Phase III FENtrepid trial for primary progressive multiple sclerosis, showing non‑inferiority to Ocrevus and a 12% risk reduction in confirmed disability progression. The drug also delivered a 26% lower risk...

By Xtalks – Biotech Blogs
Anti-Aging Gene Therapy in Alzheimer’s and ALS with Klotho Neurosciences’ Dr. Joseph Sinkule — Episode 243
News•Feb 18, 2026

Anti-Aging Gene Therapy in Alzheimer’s and ALS with Klotho Neurosciences’ Dr. Joseph Sinkule — Episode 243

The Xtalks Life Science Podcast featured Joseph Sinkule, CEO of Klotho Neurosciences, discussing the company’s secreted α‑Klotho gene therapy platform aimed at age‑related neurodegenerative diseases such as Alzheimer’s, ALS and Parkinson’s. Klotho leverages a patented anti‑aging gene to develop cell‑ and...

By Xtalks – Biotech Blogs